A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab™) in High-Risk Patients with Percutaneous Coronary Intervention

다국어 초록 (Multilingual Abstract)

Purpose: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab™. We expected to obtain same results as with ReoPro in improving ischemic cardiac complications in high-risk patients who were about to undergo percutaneous coronary intervention (PCI). Patients and Methods: Patients of 19 -80 years of age with acute coronary syndrome (ACS) who were about to undergo PCI were enrolled. After screening and confirmation of eligibility, patients were randomly assigned to different groups. Clotinab™ was given to 84 patients (58.7± 10.6 years, M:F=68:16) and ReoPro (59.0±10.5 years, M:F=30:10) was given to 40 patients before PCI. The primary efficacy endpoint was the onset of major adverse cardiac event (MACE) within 30 days from day 1. The tolerability endpoints were assessed based on bleeding, thrombocytopenia, change in Hb/Hct, human antichimetric antibody development, and adverse events. Results: The number of ClotinabTM patients experiencing MACE was 0 out of 76 per protocol (PP) patients. The MACE rate was 0%, and its 95% exact CI was [0.00- 4.74%]. A major bleeding event developed in 3 patients in the ReoPro group. The probability of MACE onset in Clotinab™ was estimated to be less than 5%. There was no clinically significant result in tolerability variables. Conclusion: ClotinabTM is an effective and safe medicine in preventing ischemic cardiac complications for high-risk patients who will receive PCI.

참고문헌 (Reference)

1 Antman EM, "The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making" 284 : 835-842, 2000

2 Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty, "The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis" 96 : 1445-1453, 1997

3 Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization, "The EPILOG Investigators" 336 : 1689-1696, 1997

4 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, "The EPIC Investigation" 330 : 956-961, 1994

5 Alexander JH, "Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT" 56 : 965-976, 1998

6 Simoons ML, "Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group" 89 : 596-603, 1994

7 Topol EJ, "Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators" 343 : 881-886, 1994

8 "Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study" 349 : 1429-1435, 1997

9 Coller BS, "Platelets and thrombolytic therapy" 322 : 33-42, 1990

10 Montalescot G, "Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction" 344 : 1895-1903, 2001

11 Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction, "Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators" 338 : 1488-1497, 1998

12 A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, "Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators" 338 : 1498-1505, 1998

13 International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators, "Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network" 97 : 2386-2395, 1998

14 Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators, "Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy" 339 : 436-443, 1998

15 Coons JC, "Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention" 39 : 1621-1626, 2005

16 Kaul DK, "Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor" 95 : 968-974, 2000

17 Brown DL, "Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention" 87 : 537-541, 2001

18 Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II, "Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II" 349 : 1422-1428, 1997

19 Ryan TJ, "Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty)" 78 : 486-502, 1988

20 Thompson RD, "Divergent effects of platelet-endothelial cell adhesion molecule-1 and beta 3 integrin blockade on leukocyte transmigration in vivo" 165 : 426-434, 2000

21 Topol EJ, "Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization" 344 : 1888-1894, 2001

22 PRICE Investigators, "Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial" 141 : 402-409, 2001

23 Kong DF, "Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease" 98 : 2829-2835, 1998

24 Hamm CW, "Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators" 340 : 1623-1629, 1999

25 Cannon CP, "American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)" 38 : 2114-2130, 2001

26 Braunwald E, "ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)" 40 : 1366-1374, 2002

27 Schömig A, "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents" 334 : 1084-1089, 1996

28 Coller BS, "A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex" 76 : 101-108, 1985